PFE has been testing $26 since February but has breached another key level Pfizer Inc (NYSE:PFE) stock is down 1.1% to trade ...

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago. These figures are ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Recent discussions on X about Pfizer's stock, ticker PFE, have centered around the company's stagnant performance and lack of significant catalysts to drive growth. Many users have expressed ...

Pfizer (PFE) fell ~5% on Tuesday as Wall Street analysts assessed mid-stage data the company posted for its obesity therapy PF-08653944 ahead of its consensus-beating Q4 2025 results, which indicated ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer ( (PFE)) has shared an update. Pfizer shareholders held their Annual Meeting on April 23, 2026, where they re-elected the full slate of board nominees, including Chief Executive Albert Bourla ...